Guangji Pharmaceutical released its 2026 interim report. During the reporting period, net profit attributable to the parent company was negative 57.9451 million yuan, a narrower loss compared with the same period last year, marking two consecutive years of narrowing losses. The company's total operating revenue was 312 million yuan, up 9.71 percent year-on-year. Net cash inflow from operating activities was 43.7281 million yuan, up 73.09 percent year-on-year, growing for three consecutive years. The company's asset-liability ratio was 74.01 percent, gross margin was 23.25 percent, and diluted earnings per share was negative 0.17 yuan.
Hubei Guangji Pharmaceutical Co LtdNet loss of 57.9451 million yuan, though narrowed, remains negative.
